BDAZ - thank you 

I'm concerned about generating revenue and getting Apabetalone to market.

My questions would be:

 - Slide 18 of the 11/17/2017 Bio Europe presentation indicates that the Betonmace trial will conclude mid 2019 with subsequent ACS EU approval mid 2020 and ACS US and Japan approval occuring in 2021.

 - Slide 29 of the Q1 2017 Corporate Update indicates 2021 market entry in the EU and Japan and 2023 market entry in the US.

Are these timelines still on track?

Are the revenue projections on slide 29 still relevant?

Chicagoest